Sanofi, a pharmaceutical company, plans to sell a 50% stake in its over-the-counter unit, Opella, to a US investment fund, CD&R, for 16 billion euros. The sale of Opella, the maker of France’s leading painkiller Doliprane, has faced political controversy in France due to concerns about jobs and domestic pharmaceutical production. The French government has approved the deal with guarantees on employment, production, and investment. CD&R and Sanofi aim to support Opella’s growth strategy as a global consumer healthcare company. The deal is expected to be finalized in the second quarter of the next year.
Source link
Sanofi pursues sale of painkiller after political controversy
